Who are Ramycin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Soriatane, Propiocine, E-Mycin, Alcidon, Actos, Abraxane.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fusidic-acid.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

Ramycin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ramycin (FUSIDIC ACID) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: fusidic acid. Area: Infectious Disease.

phase 3 fusidic acid Bile salt export pump Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Ramycin (FUSIDIC ACID). Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ramycin TARGET	FUSIDIC ACID		phase 3	fusidic acid	Bile salt export pump
Soriatane	ACITRETIN	Stiefel Labs Inc	marketed	Retinoid [EPC]	Bile salt export pump	1996-01-01
Propiocine	ERYTHROMYCIN PROPIONATE		marketed	Macrolide	Bile salt export pump, Bile salt export pump	1967-01-01
E-Mycin	erythromycin	Generic (originally Abbott/Lilly)	marketed	Macrolide [EPC]	Aldehyde oxidase, Bile salt export pump, Cytochrome P450 1B1	1952-01-01
Alcidon	GLAFENINE		marketed	glafenine	Bile salt export pump, Bile salt export pump
Actos	pioglitazone	Takeda	marketed		CDGSH iron-sulfur domain-containing protein 2, Bile salt export pump, CDGSH iron-sulfur domain-containing protein 1
Abraxane	Abraxane	The First Affiliated Hospital with Nanjing Medical University	marketed		Multidrug resistance-associated protein 7, Bile salt export pump, Melanocortin receptor 5

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (fusidic acid class)

· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ramycin — Competitive Intelligence Brief. https://druglandscape.com/ci/fusidic-acid. Accessed 2026-06-09.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing